JP2025124655A5 - - Google Patents

Info

Publication number
JP2025124655A5
JP2025124655A5 JP2025076885A JP2025076885A JP2025124655A5 JP 2025124655 A5 JP2025124655 A5 JP 2025124655A5 JP 2025076885 A JP2025076885 A JP 2025076885A JP 2025076885 A JP2025076885 A JP 2025076885A JP 2025124655 A5 JP2025124655 A5 JP 2025124655A5
Authority
JP
Japan
Prior art keywords
methods
new products
manufacturing methods
manufacturing
methods substantially
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025076885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025124655A (ja
Filing date
Publication date
Priority claimed from JP2022500119A external-priority patent/JP7751817B2/ja
Application filed filed Critical
Publication of JP2025124655A publication Critical patent/JP2025124655A/ja
Publication of JP2025124655A5 publication Critical patent/JP2025124655A5/ja
Pending legal-status Critical Current

Links

JP2025076885A 2019-07-05 2025-05-02 新規な癌抗原及び方法 Pending JP2025124655A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP19184680 2019-07-05
EP19184680.7 2019-07-05
EP20170224 2020-04-17
EP20170224.8 2020-04-17
JP2022500119A JP7751817B2 (ja) 2019-07-05 2020-07-03 新規な癌抗原及び方法
PCT/GB2020/051592 WO2021005338A2 (en) 2019-07-05 2020-07-03 Novel cancer antigens and methods

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022500119A Division JP7751817B2 (ja) 2019-07-05 2020-07-03 新規な癌抗原及び方法

Publications (2)

Publication Number Publication Date
JP2025124655A JP2025124655A (ja) 2025-08-26
JP2025124655A5 true JP2025124655A5 (https=) 2025-09-30

Family

ID=71523190

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022500119A Active JP7751817B2 (ja) 2019-07-05 2020-07-03 新規な癌抗原及び方法
JP2025076885A Pending JP2025124655A (ja) 2019-07-05 2025-05-02 新規な癌抗原及び方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022500119A Active JP7751817B2 (ja) 2019-07-05 2020-07-03 新規な癌抗原及び方法

Country Status (11)

Country Link
US (1) US20220213159A1 (https=)
EP (1) EP3993826B1 (https=)
JP (2) JP7751817B2 (https=)
KR (1) KR20220034040A (https=)
CN (1) CN114206913A (https=)
AU (1) AU2020309202A1 (https=)
BR (1) BR112022000020A2 (https=)
CA (1) CA3142329A1 (https=)
IL (1) IL289335A (https=)
MX (1) MX2022000263A (https=)
WO (1) WO2021005338A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021006941A2 (pt) 2018-10-19 2021-08-31 The Francis Crick Institute Limited Antígenos de câncer inovadores e métodos
CA3179694A1 (en) * 2020-04-17 2021-10-21 The Francis Crick Institute Limited Fusion proteins of ctl antigens for treating melanoma
JP2023522193A (ja) * 2020-04-17 2023-05-29 ザ フランシス クリック インスティチュート リミティッド 抗原プール
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
EP1586330A1 (en) 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
DK1871391T3 (da) 2005-03-30 2012-04-16 Viroxis Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
WO2006105642A1 (en) * 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
AT502292B1 (de) * 2005-05-11 2010-04-15 Avir Green Hills Biotechnology Melanomdiagnose
US8921050B2 (en) 2006-03-17 2014-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of diagnosing renal cell carcinoma
US20080019979A1 (en) 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
US8541553B2 (en) * 2007-05-24 2013-09-24 Baxter Healthcare Sa Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein
NZ622148A (en) * 2011-08-30 2016-06-24 Nat Defense Medical Ct Gene biomarkers for prediction of susceptibility of ovarian neoplasms and/or prognosis or malignancy of ovarian cancers
CN111655271B (zh) * 2017-12-28 2025-09-23 隆萨销售股份公司 用于免疫肿瘤学和抗炎疗法的外来体
CA3179694A1 (en) * 2020-04-17 2021-10-21 The Francis Crick Institute Limited Fusion proteins of ctl antigens for treating melanoma

Similar Documents

Publication Publication Date Title
JP2024156852A5 (https=)
JP2024133471A5 (https=)
JP2026012786A5 (https=)
JP2023113641A5 (https=)
JP2025023938A5 (https=)
JP2024037765A5 (https=)
JP2023113681A5 (https=)
JP2026048925A5 (https=)
JP2025106258A5 (https=)
JP2023153863A5 (https=)
JP2023164986A5 (https=)
JP2025118771A5 (https=)
JP2024156705A5 (https=)
JP2023134519A5 (https=)
JP2025038009A5 (https=)
JP2024088648A5 (https=)
JP2023103231A5 (https=)
JP2022538004A5 (https=)
JP2025143267A5 (https=)
JP2024160274A5 (https=)
JP2023139025A5 (https=)
JP2025163046A5 (https=)
JP2025124655A5 (https=)
JP2025041678A5 (https=)
JP2023154065A5 (https=)